Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis
Open Access
- 8 April 2021
- journal article
- research article
- Published by Elsevier in Cellular Immunology
- Vol. 364, 104359
Abstract
No abstract availableKeywords
Funding Information
- European and Developing Countries Clinical Trials Partnership (CDF1546)
- National Institutes of Health (5U01IA115619/03)
- Universiteit Stellenbosch
- National Research Foundation (86535)
This publication has 58 references indexed in Scilit:
- Gr1intCD11b+ Myeloid-Derived Suppressor Cells in Mycobacterium tuberculosis InfectionPLOS ONE, 2013
- Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic PerspectivesImmunological Investigations, 2012
- Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 ExpressionCancer Research, 2011
- Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally ConstrainedCancer Research, 2010
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma PatientsClinical Cancer Research, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor functionBlood, 2008
- Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancerNature Medicine, 2007
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionJournal of Experimental Medicine, 2006
- All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer PatientsCancer Research, 2006